TG THERAPEUTICS, INC. Share-based Payment Arrangement, Expense
TG THERAPEUTICS, INC. (TGTX) reported Share-based Payment Arrangement, Expense of $64.70 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-02-27
- TG THERAPEUTICS, INC. share-based payment arrangement, expense for the quarter ending 2025-06-30 was $16.40M, a 72.63% increase year-over-year.
- TG THERAPEUTICS, INC. share-based payment arrangement, expense for the quarter ending 2025-03-31 was $15.00M, a 61.29% increase year-over-year.
- TG THERAPEUTICS, INC. share-based payment arrangement, expense for the quarter ending 2024-12-31 was $11.90M, a 26.60% increase year-over-year.
- TG THERAPEUTICS, INC. share-based payment arrangement, expense for the quarter ending 2024-09-30 was $11.80M, a 28.26% increase year-over-year.
- TG THERAPEUTICS, INC. share-based payment arrangement, expense for fiscal 2025 was $64.70M, a 52.24% increase from fiscal 2024.
- TG THERAPEUTICS, INC. share-based payment arrangement, expense for fiscal 2024 was $42.50M, a 12.14% increase from fiscal 2023.
- TG THERAPEUTICS, INC. share-based payment arrangement, expense for fiscal 2023 was $37.90M, a 15.02% decline from fiscal 2022.
- TG THERAPEUTICS, INC. share-based payment arrangement, expense for fiscal 2022 was $44.60M, a 27.24% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month | Share-based Payment Arrangement, Expense 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $64.70M 10-K · filed 2026-02-27 | ||||
| 2025-06-30 | $16.40M 10-Q · filed 2025-08-08 | $31.30M 10-Q · filed 2025-08-08 | $43.30M derived: sum of 3 quarters · filed 2026-02-27 | $55.10M derived: sum of 4 quarters · filed 2026-02-27 | |
| 2025-03-31 | $15.00M 10-Q · filed 2025-05-09 | $26.90M derived: sum of 2 quarters · filed 2026-02-27 | $38.70M derived: sum of 3 quarters · filed 2026-02-27 | $48.20M derived: sum of 4 quarters · filed 2026-02-27 | |
| 2024-12-31 | $11.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $23.70M derived: sum of 2 quarters · filed 2026-02-27 | $33.20M derived: sum of 3 quarters · filed 2026-02-27 | $42.50M 10-K · filed 2026-02-27 | |
| 2024-09-30 | $11.80M 10-Q · filed 2024-11-07 | $21.30M derived: sum of 2 quarters · filed 2025-08-08 | $30.60M 10-Q · filed 2024-11-07 | $40.00M derived: sum of 4 quarters · filed 2026-02-27 | |
| 2024-06-30 | $9.50M 10-Q · filed 2025-08-08 | $18.80M 10-Q · filed 2025-08-08 | $28.20M derived: sum of 3 quarters · filed 2026-02-27 | $37.40M derived: sum of 4 quarters · filed 2026-02-27 | |
| 2024-03-31 | $9.30M 10-Q · filed 2025-05-09 | $18.70M derived: sum of 2 quarters · filed 2026-02-27 | $27.90M derived: sum of 3 quarters · filed 2026-02-27 | $40.40M derived: sum of 4 quarters · filed 2026-02-27 | |
| 2023-12-31 | $9.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $18.60M derived: sum of 2 quarters · filed 2026-02-27 | $31.10M derived: sum of 3 quarters · filed 2026-02-27 | $37.90M 10-K · filed 2026-02-27 | |
| 2023-09-30 | $9.20M 10-Q · filed 2024-11-07 | $21.70M derived: sum of 2 quarters · filed 2024-11-07 | $28.50M 10-Q · filed 2024-11-07 | $65.00M derived: sum of 4 quarters · filed 2025-03-03 | |
| 2023-06-30 | $12.50M 10-Q · filed 2024-08-09 | $19.40M 10-Q · filed 2024-08-09 | $55.80M derived: sum of 3 quarters · filed 2025-03-03 | $62.80M derived: sum of 4 quarters · filed 2025-03-03 | |
| 2023-03-31 | $6.80M 10-Q · filed 2024-05-06 | $43.30M derived: sum of 2 quarters · filed 2025-03-03 | $50.30M derived: sum of 3 quarters · filed 2025-03-03 | ||
| 2022-12-31 | $36.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $43.50M derived: sum of 2 quarters · filed 2025-03-03 | $44.60M 10-K · filed 2025-03-03 | $19.20M 10-K · filed 2024-02-29 | |
| 2022-09-30 | $7.00M 10-Q · filed 2023-11-06 | $8.10M 10-Q · filed 2023-11-06 | |||
| 2021-12-31 | $61.30M 10-K · filed 2024-02-29 | ||||
| 2019-12-31 | $11.34M 10-K · filed 2020-03-02 | ||||
| 2018-12-31 | $12.89M 10-K · filed 2020-03-02 | ||||
| 2017-12-31 | $15.95M 10-K · filed 2020-03-02 | ||||
| 2016-12-31 | $7.51M 10-K · filed 2019-03-01 | $7.51M 10-K · filed 2017-03-16 | |||
| 2016-03-31 | $1.70M 10-Q · filed 2016-05-10 | $4.56M derived: sum of 2 quarters · filed 2017-03-16 | $5.80M derived: sum of 3 quarters · filed 2017-03-16 | $12.04M derived: sum of 4 quarters · filed 2017-03-16 | |
| 2015-12-31 | $2.86M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $4.10M derived: sum of 2 quarters · filed 2017-03-16 | $10.34M derived: sum of 3 quarters · filed 2017-03-16 | $15.70M 10-K · filed 2017-03-16 | |
| 2015-09-30 | $1.24M 10-Q · filed 2015-11-09 | $7.48M derived: sum of 2 quarters · filed 2015-11-09 | $12.84M 10-Q · filed 2015-11-09 | ||
| 2015-06-30 | $6.24M 10-Q · filed 2015-08-10 | $11.60M 10-Q · filed 2015-08-10 | |||
| 2015-03-31 | $5.36M 10-Q · filed 2016-05-10 | ||||
| 2014-12-31 | $21.11M 10-K · filed 2017-03-16 | ||||
| 2013-12-31 | $5.20M 10-K · filed 2016-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |